
Eno’s responsibilities include the company’s strategic direction, commercialization efforts and day-to-day operations. His role includes these responsibilities over the HeartBeam AIMI and HeartBeam AIMIGo platforms.
The Santa Clara, California-based company designed AIMIGo as a credit card-sized, 12-lead 3D vector electrocardiogram (ECG) device. It developed AIMI for acute care settings. AIMI provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack.
Eno said in a news release that he feels “privileged” to join HeartBeam as it prepares for a new phase of commercialization. The company said last month that it expects FDA approval for its AIMI platform this year.
“I am impressed with what the team has accomplished, and I believe that HeartBeam’s technology will be able to make a major impact on the lives of the millions of people who suffer from cardiac-related issues, said Eno. “I look forward to helping to establish the HeartBeam platform as the new standard of care for ambulatory-based cardiology.”
About the new HeartBeam president
Eno brings with him more than 28 years of experience, according to HeartBeam. He created go-to-market strategies for a range of breakthrough products.
Before HeartBeam, Eno served as CEO of Preview Medical, a diagnostic equipment company. Prior to that, he held the role of SVP for marketing at HeartFlow. There, he led all aspects of marketing and product functions for the company’s noninvasive testing for heart disease.
Other roles held by Eno include senior marking and sales leadership positions at OptimMedica, NeoGuide Systems and Avantec Vascular.
“We have a tremendous opportunity to accelerate our company growth as we move forward on our commercialization path, and we’re excited to have Rob join our leadership team,” said Branislav Vajdic, HeartBeam CEO and founder. “Rob has extensive experience bringing innovative medical technology products to market, which will be invaluable as we move forward with plans to broaden our product portfolio pipeline.”